|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 1867-1874.
Prepublished online as a Blood First Edition Paper on November 4, 2004; DOI 10.1182/blood-2004-10-3856.
Previous Article | Next Article 
Submitted October 6, 2004
Accepted October 27, 2004
Iron trafficking in the mitochondrion: novel pathways revealed by disease
Ian Napier, Prem Ponka, and Des R Richardson*
Iron Metabolism and Chelation Program, Children's Cancer Institute Australia for Medical Research, Sydney, New South Wales, Australia
Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
* Corresponding author; email: d.richardson{at}ccia.org.au.
It is well known that iron (Fe) is transported to the mitochondrion for heme synthesis. However, only recently has the importance of this organelle for many other facets of Fe metabolism become widely appreciated. Indeed, this was stimulated by the description of human disease states that implicate mitochondrial Fe metabolism. In particular, studies assessing various diseases leading to mitochondrial Fe-loading have produced intriguing findings. For instance, the disease, X-linked sideroblastic anemia with ataxia (XLSA/A), is due to a mutation in the ABCB7 transporter that is thought to transfer [Fe-S] clusters from the mitochondrion to the cytoplasm. This and numerous other findings suggest the mitochondrion is a dynamo of Fe metabolism, being not only vital for heme synthesis, but playing a critical role in the genesis of [Fe-S] clusters. Studies examining the disease, Friedreichs ataxia, have suggested that a mutation in the gene encoding frataxin leads to mitochondrial Fe-loading. Apart from these findings, the recent discovery of mitochondrial ferritin that may store Fe in ring sideroblasts, may regulate the level of Fe needed for heme and [Fe-S] cluster synthesis. In this review, we suggest a model of mitochondrial Fe processing that may account for the pathology observed in these disease states.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Cellular iron metabolism: mitochondria in the spotlight
- Christopher R. Chitambar
Blood 2005 105: 1844-1845.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
W. Chen, P. N. Paradkar, L. Li, E. L. Pierce, N. B. Langer, N. Takahashi-Makise, B. B. Hyde, O. S. Shirihai, D. M. Ward, J. Kaplan, et al.
From the Cover: Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria
PNAS,
September 22, 2009;
106(38):
16263 - 16268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L.-H. Huang, E. M. Becker, M. Whitnall, Y. S. Rahmanto, P. Ponka, and D. R. Richardson
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant
PNAS,
September 22, 2009;
106(38):
16381 - 16386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Stachura, J. R. Reyes, P. Bartunek, B. H. Paw, L. I. Zon, and D. Traver
Zebrafish kidney stromal cell lines support multilineage hematopoiesis
Blood,
July 9, 2009;
114(2):
279 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ramirez, E. J. Zabaleta, and L. Lamattina
Nitric oxide and frataxin: two players contributing to maintain cellular iron homeostasis
Ann. Bot.,
June 25, 2009;
(2009)
mcp147v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Iolascon, L. De Falco, and C. Beaumont
Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis
Haematologica,
March 1, 2009;
94(3):
395 - 408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Jeong, K. I. Rathore, K. Schulz, P. Ponka, P. Arosio, and S. David
Dysregulation of Iron Homeostasis in the CNS Contributes to Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
J. Neurosci.,
January 21, 2009;
29(3):
610 - 619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Campanella, E. Rovelli, P. Santambrogio, A. Cozzi, F. Taroni, and S. Levi
Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia
Hum. Mol. Genet.,
January 1, 2009;
18(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Kakhlon, H. Manning, W. Breuer, N. Melamed-Book, C. Lu, G. Cortopassi, A. Munnich, and Z. I. Cabantchik
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
Blood,
December 15, 2008;
112(13):
5219 - 5227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. Paw
Iron Does Not "Jiggle Free" in Mitochondria: Is Mitoferrin the Only Answer?.
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
sci-27 - sci-27.
[Abstract]
|
 |
|

|
 |

|
 |
 
M. Tian, D. R. Campagna, L. S. Woodward, M. J. Justice, and M. D. Fleming
hem6: an ENU-induced recessive hypochromic microcytic anemia mutation in the mouse
Blood,
November 15, 2008;
112(10):
4308 - 4313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Lim, D. S. Kalinowski, and D. R. Richardson
Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class
Mol. Pharmacol.,
July 1, 2008;
74(1):
225 - 235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Burke, R. K. Mutharasan, and H. Ardehali
The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the KATP Channel
Circ. Res.,
February 1, 2008;
102(2):
164 - 176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Weiss
Iron caught on the shuttle
Blood,
February 1, 2008;
111(3):
980 - 980.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-S. Sohn, W. Breuer, A. Munnich, and Z. I. Cabantchik
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications
Blood,
February 1, 2008;
111(3):
1690 - 1699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shvartsman, R. Kikkeri, A. Shanzer, and Z. I. Cabantchik
Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications
Am J Physiol Cell Physiol,
October 1, 2007;
293(4):
C1383 - C1394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Missirlis, S. Kosmidis, T. Brody, M. Mavrakis, S. Holmberg, W. F. Odenwald, E. M. C. Skoulakis, and T. A. Rouault
Homeostatic Mechanisms for Iron Storage Revealed by Genetic Manipulations and Live Imaging of Drosophila Ferritin
Genetics,
September 1, 2007;
177(1):
89 - 100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Wallenborn, J. K. McGee, M. C. Schladweiler, A. D. Ledbetter, and U. P. Kodavanti
Systemic Translocation of Particulate Matter-Associated Metals Following a Single Intratracheal Instillation in Rats
Toxicol. Sci.,
July 1, 2007;
98(1):
231 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Cavadini, G. Biasiotto, M. Poli, S. Levi, R. Verardi, I. Zanella, M. Derosas, R. Ingrassia, M. Corrado, and P. Arosio
RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload
Blood,
April 15, 2007;
109(8):
3552 - 3559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Richardson and D. B. Lovejoy
"Iron mining" to inhibit tumor growth
Blood,
October 1, 2006;
108(7):
2140 - 2140.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nie, G. Chen, A. D. Sheftel, K. Pantopoulos, and P. Ponka
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin
Blood,
October 1, 2006;
108(7):
2428 - 2434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sheikh, D. S. Batusic, J. Dudas, K. Tron, K. Neubauer, B. Saile, and G. Ramadori
Hepcidin and hemojuvelin gene expression in rat liver damage: in vivo and in vitro studies
Am J Physiol Gastrointest Liver Physiol,
September 1, 2006;
291(3):
G482 - G490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. De, J. Bell, N. J. Blackburn, R. E. Mains, and B. A. Eipper
Role for an Essential Tyrosine in Peptide Amidation
J. Biol. Chem.,
July 28, 2006;
281(30):
20873 - 20882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Kalinowski and D. R. Richardson
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Pharmacol. Rev.,
December 1, 2005;
57(4):
547 - 583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Glickstein, R. Ben El, M. Shvartsman, and Z. I. Cabantchik
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
Blood,
November 1, 2005;
106(9):
3242 - 3250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Xu, H. L. Persson, and D. R. Richardson
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Mol. Pharmacol.,
August 1, 2005;
68(2):
261 - 271.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|